Nephrology Times
Advertisement
A study examined the efficacy and safety of conversion from treatment with the long-acting ESA MPG-EPO to vadadustat.
Wei Ling Lau, MD, discussed the potential impact of AccurKardia's AK+ Guard hyperkalemia detection software.
Researchers examined ULT and the risk of CKD progression among patients with impaired kidney function and gout.
What is the association of gout with CV disease and mortality risk in patients with type 2 diabetes and can CKD modify it?
A secondary analysis of DCP trial data sought to understand the effects of thiazide diuretics on kidney outcomes.
Researchers studied the associations among patient characteristics, CKRT prescription, and survival in pediatric patients.
Researchers summarized findings on dietary interventions to reduce acid load to manage metabolic acidosis in adults with CKD.
The American Kidney Fund is providing emergency financial aid to patients impacted by the California wildfires.
The EMPA-KIDNEY trial examined the effects of SGLT2 inhibition on uric acid and gout in patients with CKD.
A study identified modifiable dialysis-related factors associated with fatigue and dialysis recovery time.
The renal effects and safety of acetazolamide in patients with type 1 diabetes was the subject of a recent study.
The International Society of Nephrology (ISN) has announced the 2025 recipients of the ISN Awards and ISN Pioneer Awards.
Researchers studied the association between chronic kidney disease and postoperative complications.
The American Kidney Fund has named Pranav Garimella as its first chief medical officer.
Evergreen Nephrology has raised $130 million in capital to expand its value-based care model for kidney disease.
Researchers studied the association of obesity severity and duration with chronic kidney disease incidence.
A study examined whether serum phosphate levels could predict kidney outcomes in patients with ADPKD.
Sarah Tolson shares what billing departments of dialysis programs need to know about the CMS final rule for the ESRD PPS.
An exploratory pilot study aimed to identify and evaluate potential proinflammatory biomarkers in patients with ADPKD.
The FDA rejected Zynquista as an add-on to insulin therapy for adults with type 1 diabetes and CKD.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.